Phase
Condition
Chest Pain
Arrhythmia
Cardiac Disease
Treatment
Remimazolam
Propofol
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Atrial fibrillation (AF) (paroxysmal, persistent or long standing persistent) withindication for catheter ablation
Age above 18 years
Capacity to give informed consent
Exclusion
Exclusion Criteria:
Heart failure (NYHA III-IV), irrespective of left ventricular ejection fraction
Left ventricular ejection fraction < 20%
Significant valvulopathy (moderate or severe aortic stenosis, severe mitralregurgitation, severe aortic regurgitation, moderate and severe mitral stenosis,severe tricuspid regurgitation)
Obstructive sleep apnoea syndrome (AHI >30)
Low oxygen saturation (<93%) at baseline
High aspiration risk (hiatal hernia, gastroesophageal reflux disease on chronicpharmacotherapy)
Hypersensitivity to the study drugs
Chronic kidney disease (stage 4 and 5 of CKD), liver cirrhosis
Anticipated difficult airways
ASA (American Society of Anaesthesiologists) score > 4
Schizophrenia
Epilepsy
Other individual contraindications (will be reported in detail)
Study Design
Connect with a study center
University Hospital Kralovske Vinohrady
Prague, 10034
CzechiaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.